Frederic J. Kaye

Frederic J. Kaye

Auto-generated profile, based on publicly available information

Frederic J. Kaye

Department of Medicine, University of Florida College of Medicine, Gainesville, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BCBenjamin C. Creelan
Benjamin C. Creelan
CWChao Wang
Chao Wang
JTJamie K. Teer
Jamie K. Teer
ETEric M. Toloza
Eric M. Toloza
JYJiqiang Yao
Jiqiang Yao
SAScott J. Antonia
Scott J. Antonia

2 January 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
Sajid KhanSajid Khan
Sajid Khan
PKPatrick Kellish
Patrick Kellish
NKNick Konidaris
Nick Konidaris
DTDinesh Thummuri
Dinesh Thummuri
JWJanet Wiegand
Janet Wiegand
DZDaohong Zhou
Daohong Zhou
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-XL and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family anti-apoptotic proteins, except BCL-2 inhibitors, are not clinically relevant because of various on-target toxicities. We, therefore, aimed to develop an effective and safe strategy targeting these anti-apoptotic proteins with DT2216 (our platelet-sparing BCL-XL degrader) and AZD8055 (an mTOR inhibitor) to avoid associated on-target toxicities while synergistically optimizing tumor response. Through BH3 mimetic screening, we identified a subset of SCLC cell lines that is co-dependent on BCL-XL and MCL-1. After screening inhibitors of selected tumorigenic pathways, we found that AZD8055 selectively downregulates MCL-1 in SCLC cells and its combination with DT2216 synergistically killed BCL-XL/MCL-1 co-dependent SCLC cells, but not normal cells. Mechanistically, the combination caused BCL-XL degradation and suppression of MCL-1 expression, and thus disrupted MCL-1 interaction with BIM leading to an enhanced apoptotic induction. In vivo, the DT2216 + AZD8055 combination significantly inhibited the growth of cell line-derived and patient-derived xenografts and reduced tumor burden accompanied by increased survival in a genetically engineered mouse model of SCLC without causing appreciable thrombocytopenia or other normal tissue injuries. Thus, these preclinical findings lay a strong foundation for future clinical studies to test DT2216 + mTOR inhibitor combinations in a subset of SCLC patients whose tumors are co-driven by BCL-XL and MCL-1.

27 April 2023 in Oncogene
Verified
Journal Article
Open access
PDF file
MGMaria V. Guijarro
Maria V. Guijarro
ANAkbar Nawab
Akbar Nawab
PDPeter Dib
Peter Dib
SBSandra Burkett
Sandra Burkett
XLXiaoping Luo
Xiaoping Luo
MZMaria Zajac-Kaye
Maria Zajac-Kaye
We previously showed that elevated TYMS exhibits oncogenic properties and promotes tumorigenesis after a long latency, suggesting cooperation with sequential somatic mutations. Here we report the cooperation of ectopic expression of human TYMS with loss of Ink4a/Arf, one of the most commonly mutated somatic events in human cancer. Using an hTS/Ink4a/Arf−/− genetically engineered mouse model we showed that deregulated TYMS expression in Ink4a/Arf null background accelerates tumorigenesis and metastasis. In addition, tumors from TYMS-expressing mice were associated with a phenotype of genomic instability including enhanced double strand DNA damage, aneuploidy and loss of G1/S checkpoint. Downregulation of TYMS in vitro decreased cell proliferation and sensitized tumor cells to antimetabolite chemotherapy. In addition, depletion of TYMS in vivo by TYMS shRNA reduced tumor incidence, delayed tumor progression and prolonged survival in hTS/Ink4a/Arf−/− mice. Our data shows that activation of TYMS in Ink4a/Arf null background enhances uncontrolled cell proliferation and tumor growth, supporting the development of new agents and strategies targeting TYMS to delay tumorigenesis and prolong survival.

1 January 2002
Verified
Book Chapter
Closed access
FKFrederic J. Kaye
Frederic J. Kaye

1 January 2016 in Molecular Cancer Research
Verified
Journal Article
Closed access
CCChunxia Cao
Chunxia Cao
RGRuli Gao
Ruli Gao
MZMin Zhang
Min Zhang
AAAntonio L. Amelio
Antonio L. Amelio
MFMohammad Fallahi
Mohammad Fallahi
FKFrederic J. Kaye
Frederic J. Kaye
Cyclooxygenase-2 (COX-2) directs the synthesis of prostaglandins important for mitogenic signaling. Here we report that COX-2 is a transcriptional target of the CREB co-activator CRTC1. In addition, we detected a correlation between the LKB1-null status and presence of 72/74 kDa glycosylated COX-2, but not inactive hypoglycosylated COX-2 in fresh lung adenocarcinoma samples. Since CRTC1 is suppressed by cytoplasmic shuttling following LKB1/AMPK/SIK phosphorylation, we developed an LKB1 signature in lung cancer to search the Connectivity-MAP drug response database. Remarkably, all high-ranking drugs positively associated with the LKB1-null signature were known CRTC1 activators. Somatic LKB1 mutations are present in 20% of lung adenocarcinomas and we observed growth and cell motility inhibition with COX-2 inhibitors in LKB1-null lung cancer cells with activated CRTC1, but negligible inhibition in LKB1-wildtype cells. In summary, the CREB co-activator CRTC family directly links LKB1 with COX-2 activation and provides a new framework for selecting patients for COX-2 inhibition.